Activiomics, UCB Collaborate on Cell-Signaling Pathway Activity | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Phosphoproteomics firm Activiomics today announced a technology agreement with biopharmaceutical company UCB to gain insight into the signaling mechanisms of therapeutic antibodies in relevant cell-based systems.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Being born premature shouldn't mean infants with high blood sugar levels don't undergo genetic testing for neonatal diabetes, a study in Pediatrics says.

In Cell this week: phosphoproteomic patterns in prostate cancer, effect of gene expression on fitness in yeast, and more.

Scripps Research Institute investigators peer back at the RNA world.

In PNAS this week: chromosome instability in S. cerevisiae, structural differences and sequence divergence in rice, and more.